Previous close | 0.0500 |
Open | 0.0300 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 1.50 |
Expiry date | 2024-05-17 |
Day's range | 0.0300 - 0.0500 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Ginkgo Bioworks Holdings ( NYSE:DNA ) First Quarter 2024 Results Key Financial Results Revenue: US$37.9m (down 53% from...
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2024. The update, including a webcast slide presentation with additional details on the first quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.
GreenLab, an emerging next generation plant-biotechnology company producing complex proteins in corn, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. Together, GreenLab and Ginkgo aim to enable production of brazzein, a sweet-tasting protein found in the fruit of the native West African Oubli plant, at commercial scale. The two companies have previously partnered on a project to develop an enzyme for